Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-01-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于继续使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about continuing to use temporarily idle raised funds for cash management. It details the board and supervisory approvals, investment scope, risk controls, and regulatory compliance. It references the company's fundraising and regulatory approvals but does not contain financial statements or detailed financial results. The document is relatively short (3556 characters) and serves as a formal disclosure of a financing-related operational decision rather than a full financial report or audit. It fits the description of a Capital/Financing Update (CAP) as it updates on the use of raised capital and cash management activities. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or report publication announcement. Therefore, the best classification is CAP with high confidence.
2025-01-22 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司继续使用部分暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from Haitong Securities regarding the continued use of temporarily idle raised funds by Maiwei (Shanghai) Biotechnology Co., Ltd. for cash management. It references regulatory guidelines, approval by the board and supervisory committee, and the scope and risk control of the cash management activities. The document is not a financial report itself but a verification opinion related to the use of raised funds. It does not contain financial statements or earnings data. The document length is 3117 characters, which is relatively short and focused on a specific regulatory compliance matter. This fits best with the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2025-01-22 Chinese
迈威生物第二届监事会第十五次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by the company 迈威（上海）生物科技股份有限公司. It details the meeting date, attendance, and the approval of a proposal regarding the continued use of temporarily idle raised funds for cash management. The document references compliance with regulatory rules and states the voting results. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of a board/committee decision related to fund management, which aligns with a Capital/Financing Update (CAP) filing type rather than a full report or regulatory filing. The document length is short and focused on a specific financing-related decision, not a general regulatory announcement or report publication. Therefore, the best classification is Capital/Financing Update (CAP).
2025-01-22 Chinese
迈威生物2024年年度业绩预告
Regulatory Filings Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) for the full fiscal year 2024, with estimated net profit figures and explanations for the expected loss. It explicitly states that the data is preliminary and unaudited, and that the final audited annual report will be published later. The document is short (1160 characters) and serves as a forecast announcement rather than a full financial report. It does not contain actual financial statements or detailed analysis, only preliminary estimates and risk disclosures. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of forecasted financial results, not the actual Annual Report (10-K) or Interim Report (IR).
2025-01-17 Chinese
迈威生物自愿披露关于9MW2821联合特瑞普利单抗一线治疗尿路上皮癌纳入突破性治疗品种公示名单的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company about a drug (9MW2821) being included in a breakthrough therapy designation list by the National Medical Products Administration (NMPA) in China. It provides clinical trial data, regulatory status, and risk warnings. The document is relatively short (2633 characters) and is an announcement of a regulatory or clinical development event rather than a financial report or detailed regulatory filing. It does not contain financial statements, management discussion, or detailed governance information. It is not a report publication announcement since it is not announcing the release of a report but rather disclosing a regulatory milestone and clinical data. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about drug development progress and regulatory status.
2025-01-08 Chinese
迈威生物关于开立募集资金专项账户并签订募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of a special account for raised funds and the signing of a tripartite supervision agreement related to the management and use of those funds. It details the background of the fundraising, the signing of the agreement, and the responsibilities of involved parties. There are no financial statements or substantive financial data presented. The document is relatively short (2927 characters) and serves as a formal announcement about the fundraising account and regulatory compliance rather than a full financial report or audit. Therefore, it fits best into the category of Capital/Financing Update (CAP).
2025-01-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.